IMARC’s new report “United States Diabetes Market Report: 2019 - 2024” comprehensively discusses the US diabetes market. With more than 27 Million diabetes patients in the US, it represented the world’s third largest diabetes patient pool in 2018. The prevailing cases of diabetes are largely due to rising obesity levels and an increasing aging population. It has been found in the report that more than half of the US population is either obese or overweight which is mainly due to their sedentary lifestyles, physical inactivities and unhealthy eating habits. Furthermore, the aging population in the US has been on the rise since the 1960’s. People aged 65 years and above accounted for around 9% of the total population in 1960 while in 2018, this age group accounted for around 15% of the entire US population. Driven by rising incidences of diabetes and the fact that the US has one of the highest per capita healthcare expenditures, the US market for diabetes drugs has grown at a CAGR of around 11.8% during 2011-2018, reaching a value of US$ 45.4 Billion in 2018.
The report has provided analysis of the population and prevalence rates of diabetes on the basis of type, region, gender and age group. The report finds that compared to Type-1 diabetes, Type-2 diabetes represents the more prevalent type, accounting for the majority of all diagnosed diabetes cases. Based on regions, urban areas currently consist of the majority of the diabetes patients as compared to rural areas. Based on gender, females presently account for the majority of the total diabetes patients. In terms of age groups, the age group 40-59 currently accounts for the majority of the total diabetes patients in the US followed by the age group 60-79 and 20-39.
The report has further segmented the US diabetes market according to drug types. The market currently consists of insulin and oral anti-diabetics, with insulin accounting for the majority of the total sales. For each of the two drug types, the report has also provided historical market trends, market breakup by class, key players and market outlook. On the basis of class, Long Acting Insulin represent the biggest class in the insulin market while DPP-IV inhibitors represent the biggest class in the oral anti-diabetics market.
This report provides an analytical and statistical insight into the US diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in the United States. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the US diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the US diabetes industry in any form.
What we have achieved in this report:
Comprehensive situation analysis of the US diabetes epidemiology and its dynamics:
Focus of the Analysis:
- Historical, current and future prevalence of diabetes in US
- Historical, current and future prevalence of type-1 and type-2 diabetes in US
- Historical, current and future prevalence of diabetes in the urban and rural regions in US
- Historical, current and future prevalence of diabetes among males and females in US
- Historical, current and future prevalence of diabetes among various age groups in US
- Historical, current and future diagnosis rates for diabetes in US
- Historical, current and future drug treatment rates for diabetes in US
Comprehensive situation analysis of the US Oral Antidiabetics market and its dynamics:
Focus of the Analysis:
- Performance of the Oral Antidiabetics market in US
- Performance of key classes
- Performance of key players
- Market outlook
Comprehensive situation analysis of the US Insulin market and its dynamics:
Focus of the Analysis:
- Performance of the Insulin market in US
- Performance of key classes
- Performance of key players
- Market outlook
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Diabetes Disease Overview
5.1 What is Diabetes?
5.2 Diabetes Diagnosis and Treatment
5.2.1 Diagnosis
5.2.2 Treatment
5.3 Diabetes Complications
6 US Diabetes Epidemiology
6.1 Diabetes Population and Prevalence Rates
6.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2)
6.3 Population and Prevalence Rates by Region
6.4 Population and Prevalence Rates by Gender
6.5 Population and Prevalence Rates by Age Group
7 US Diabetes Market
7.1 Market Overview
7.2 Market Performance
7.3 Market Forecast
7.4 SWOT Analysis
7.4.1 Overview
7.4.2 Strengths
7.4.3 Weaknesses
7.4.4 Opportunities
7.4.5 Threats
7.5 Value Chain Analysis
7.6 Porter’s Five Forces Analysis
7.6.1 Overview
7.6.2 Bargaining Power of Buyers
7.6.3 Bargaining Power of Suppliers
7.6.4 Degree of Competition
7.6.5 Threat of New Entrants
7.6.6 Threat of Substitutes
7.7 Market Breakup by Segment
7.7.1 US Oral Antidiabetics Market
7.7.1.1 Historical Market Trends
7.7.1.2 Market Breakup by Class
7.7.1.3 Market Shares of Key Players
7.7.1.4 Market Forecast
7.7.2 US Insulin Market
7.7.2.1 Historical Market Trends
7.7.2.2 Market Breakup by Class
7.7.2.3 Market Shares of Key Players
7.7.2.4 Market Forecast
8 Competitive Landscape
8.1 Competitive Structure
8.2 Key Players
8.3 Profiles of Key Players
List of Figures
Figure 1: The Impact of Diabetes in the Human Body
Figure 2: Diabetes Complications
Figure 3: Global: Breakup of Diabetes Patients by Region, (in %) 2018 & 2024
Figure 4: US: Overweight & Obese Population (in Million), 2011, 2018 & 2024
Figure 5: Body Mass Index and Relative risk of Type-2 Diabetes
Figure 6: US: Breakup of Total Population by Age Groups (0-14, 15-64 & 65+, in %), 2018
Figure 7: US: Diabetes Prevalence by Age Groups (in %), 2018
Figure 8: US: Total Number of Diabetes Patients (in ‘000), 2011-2018
Figure 9: US: Total Number of Diabetes Patients Forecast (in ‘000), 2019-2024
Figure 10: US (Type1 & Type2): Total Number of Diabetes Patients (in 000), 2011-2018
Figure 11: US (Type1 & Type2): Total Number of Diabetes Patients (in 000), 2019-2024
Figure 12: US (Urban & Rural): Total Number of Diabetes Patients (in 000), 2011 -2018
Figure 13: US (Urban & Rural): Total Number of Diabetes Patients (in 000), 2019-2024
Figure 14: US (Male & Female): Total Number of Diabetes Patients (in 000), 2011-2018
Figure 15: US (Male & Female): Total Number of Diabetes Patients (in 000), 2019-2024
Figure 16: US: Total Number of Diabetes Patients by Age Group (20-39, 40-59 & 60-79, in ‘000), 2011-2018
Figure 17: US: Total Number of Diabetes Patients by Age Group (20-39, 40-59 & 60-79, in ‘000), 2019-2024
Figure 18: US: Diabetes Drug Industry Overview
Figure 19: US: Diabetes Drug Market: Sales Value (in Million US$), 2011-2018
Figure 20: US: Diabetes Drug Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 21: US: Diabetes Drug Market: SWOT Analysis
Figure 22: US: Diabetes Drug Market: Value Chain Analysis
Figure 23: US: Diabetes Drug Market: Porters Five Forces Analysis
Figure 24: US: Diabetes Drug Market: Breakup of Insulin and Oral Antidiabetics (in %), 2011-2018
Figure 25: US: Diabetes Drug Market Forecast: Breakup of Insulin and Oral Antidiabetics (in %), 2019-2024
Figure 26: US: Oral Antidiabetics Market: Sales Value (in Million US$), 2011-2018
Figure 27: US: Oral Antidiabetics Market: Sales Share of Key Classes (in %), 2011 & 2018
Figure 28: US: Oral Anti-diabetics Market: Sales Share of Key Players (in %)
Figure 29: US: Oral Antidiabetics Market: Sales Value (in Million US$), 2019-2024
Figure 30: US: Insulin Market, (in Million US$), 2011-2018
Figure 31: US: Breakup of Insulin Market by Class (in %), 2018
Figure 32: US: Insulin Market: Sales Share of Key Players (in %)
Figure 33: US: Insulin Market Forecast: Sales Value (in Million US$), 2019-2024
List of Tables
Table 1: Diagnosis of Diabetes
Table 2: Global: Diabetes Population Breakup by Country (in 000’s), 2018 & 2024
Table 3: US: Overweight & Obesity Statistics, 2011, 2018 & 2024
Table 4: US: Breakup of Total Population by Age Groups (0-14, 15-64 & 65+, in Million)
Table 5: US: Total Prevalence & Number of Diabetes Patients (in ‘000), 2011, 2018 & 2024
Table 6: US (Type1 & Type2): Total Prevalence & Number of Diabetes Patients (in ‘000), 2011, 2018 & 2024
Table 7: US (Urban & Rural): Total Prevalence & Number of Diabetes Patients (in ‘000), 2011, 2018 & 2024
Table 8: US (Male & Female): Total Prevalence & Number of Diabetes Patients (in ‘000), 2011, 2018 & 2024
Table 9: US: Total Prevalence & Number of Diabetes Patients by Age Group (20-39, 40-59 & 60-79, in ‘000), 2011, 2018 & 2024
Table 10: US: Diabetes Drug Market: Competitive Structure
Table 11: US: Diabetes Drug Market: Key Players